TG THERAPEUTICS, INC.: 10-K filed 2015-03-16

Name: TG THERAPEUTICS, INC.: 10-K filed 2015-03-16
Creator: TG THERAPEUTICS, INC.

What TG THERAPEUTICS, INC. reported in its annual report filed 2015-03-16 (fiscal FY 2014): 26 published measures, 54 facts as tagged in accession 0001144204-15-016369.

This filing

Form: 10-K (annual report)
Filed: 2015-03-16
Fiscal period: fiscal FY 2014
Accession: 0001144204-15-016369 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TG THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-12-31	86,746,890	USD
At 2013-12-31	48,112,390	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-12-31	6,645,006	USD
At 2013-12-31	8,057,898	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-12-31	55,713,784	USD
At 2013-12-31	40,485,466	USD
At 2012-12-31	16,455,995	USD

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	18,570	USD	365
2013-01-01 to 2013-12-31	5,681	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-12-31	-95,185,280	USD
At 2013-12-31	-39,404,003	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	0	USD	365
2013-01-01 to 2013-12-31	0	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-12-31	20,357	USD
At 2013-12-31	5,718	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	21,105,292	USD	365
2013-01-01 to 2013-12-31	5,203,148	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	-55,721,092	USD	365
2013-01-01 to 2013-12-31	-22,965,989	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-12-31	85,215,029	USD
At 2013-12-31	42,303,263	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	930,701	USD	365
2013-01-01 to 2013-12-31	952,888	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-12-31	5,121,196	USD
At 2013-12-31	6,317,178	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2014-12-31	799,391	USD
At 2013-12-31	799,391	USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	0	USD	365
2013-01-01 to 2013-12-31	149,799	USD	365

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	55,873,473	USD	365
2013-01-01 to 2013-12-31	23,118,370	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	40,086,347	USD	365
2013-01-01 to 2013-12-31	13,662,680	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-12-31	44,932,939	shares
At 2013-12-31	34,294,926	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-12-31	175,476,521	USD
At 2013-12-31	79,658,490	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2014-12-31	80,101,884	USD
At 2013-12-31	40,054,492	USD
At 2012-12-31	15,550,301	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2014-12-31	137,101	USD
At 2013-12-31	85,121	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2014-12-31	0	USD
At 2013-12-31	0	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	-55,781,277	USD	365
2013-01-01 to 2013-12-31	-20,478,210	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	15,787,126	USD	365
2013-01-01 to 2013-12-31	6,658,090	USD	365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	3,931	USD	365
2013-01-01 to 2013-12-31	1,127	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	-60,185	USD	365
2013-01-01 to 2013-12-31	2,487,779	USD	365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	48,900,000	USD	365
2013-07-01 to 2013-07-18	35,000,000	USD	18

Inspect the source

Entity: TG THERAPEUTICS, INC. / CIK 0001001316
Captured: 2026-09-20T05:11:16.212Z
SEC response SHA-256: 153d276440c1903144d2ca193676af4b7014428a3e4b5524efe33528427880b3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001001316.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))